JPFOPHA@EC2609A

LEOCH INT'L

METASPACEX

TRANSTECH

EXTREME VISION

ETS GROUP

RUICHANG INTL

GOLDEN FAITH GP

GLOBALSTRAT

WINSHINE SCI

HK.AI CAPITAL

600196

00656

Fosun International Holds 2025 Annual Results Presentation: Fosun has the Ability to Navigate Through Cycles | FOSUF Stock News

StockTitan

FOSUN PHARMA

FOSUN INTL

Fosun International Holds 2025 Annual Results Presentation: Fosun has the Ability to Navigate Through Cycles | FOSUF Stock News

512290

588130

159892

562600

159992

159316

159837

516500

512010

159506

520880

159849

520690

510660

02196

Fosun Pharmaceutical to Set Up Parallel Fund Structure

marketscreener

Guotai CSI Bio-medicine ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

First Trust NYSE Arca Biotech Index Fd

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Fosun Pharmaceutical to Set Up Parallel Fund Structure

Fosun International (SEHK:656) reported H1 FY 2025 revenue of C¥87.3b and basic EPS of C¥0.08, contrasting with a trailing twelve-month loss of C¥23.4b on revenue of C¥173.4b. Despite a recent profit of C¥661.8m, concerns persist over earnings quality and debt coverage, with a five-year loss growth of 77.7% annually. Bulls see potential for improvement, while bears highlight ongoing risks. The stock trades at a low P/S of 0.2x, with a DCF fair value of HK$30.90, indicating market caution amid profitability challenges.

Simplywall

Fosun International (SEHK:656) Returns To Profit In H1 EPS Profit Tests Bearish Loss Narrative

TEVA

Fosun Pharma Wins China Trial Nod for Teva-Partnered Cancer Drug FXB0871

Tip Ranks

Teva Pharmaceutical Industries

China Southern Hang Seng Biotech ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huaan Hang Seng Biotech ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Hwabao WP CSI Pharmaceuticals ETF

ICBCCS SSE STAR Biology and Medicine ETF

Fosun Pharma Wins China Trial Nod for Teva-Partnered Cancer Drug FXB0871

Shanghai Fosun Pharma announces approval from NMPA for clinical trial of FXB0871

Shanghai Fosun Pharma announces approval from NMPA for clinical trial of FXB0871

Fosun International reported its 2025 annual results, with total revenue of RMB173.43 billion and an adjusted profit of RMB4 billion. The company faced a one-off book loss of RMB23.4 billion due to non-cash impairments, primarily in real estate. Despite this, Fosun's core businesses, particularly pharmaceuticals and insurance, showed strong performance, with Fosun Pharma's net profit rising 21.69% and Fosun Insurance Portugal achieving a 15.8% increase in net profit. The company aims to optimize its asset structure and focus on high-growth areas, reflecting confidence in its strategic direction.

Asian Corporate Newswire

A Closer Look at Fosun International 2025 Annual Results: 'One-Off Risk Clearance' Paves Way for 'RMB10 Billion Profit'

Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas | FOSUF Stock News

Guo Guangchang: Fosun International's NAV reaches HKD18.1 Per Share, Focusing Resources on Core, High‑Growth Areas | FOSUF Stock News

512200

159768

Fosun International is advancing its plan to spin off the Atlantis Sanya resort business through a commercial real estate REIT on the Shanghai Stock Exchange. The company has received acceptance notices from regulatory bodies, indicating smooth progress in the application process. The spin-off will involve a new project company, Sanya Fosun Tourism Management Co., Ltd., and aims to optimize capital structure and unlock operational value. Hainan Atlantis Commercial and Tourism Development will manage the asset and subscribe for at least 20% of the REIT units. The listing is subject to regulatory approval.

China Southern CSI All Share Real Estate ETF

Yinhua CSI Interior Real Estate Theme ETF

Fosun Advances REIT Spin-Off of Atlantis Sanya on Shanghai Exchange

Guangdong province in China has approved 25 hospitals to pilot international medical services, primarily for patients with international insurance or those paying out of pocket. The hospitals, including public and private institutions, will set their own prices and maintain a separation between basic and international services. The demand for medical treatment from foreign nationals in Guangdong has significantly increased. Fosun Chancheng International Medical Center, part of this initiative, aims to enhance service quality and attract more international patients, while facing challenges in payment standards and service processes.

Yicai

Guangdong Approves First Batch of 25 Hospitals for Int’l Medical Services Pilot

Fosun International reported a total revenue of RMB173.43 billion for 2025, with overseas revenue at RMB94.86 billion, accounting for 54.7% of total revenue. The company aims for a profit of RMB10 billion and plans to increase its dividend payout ratio from 20% to 35% for the 2026 financial year. Despite a book loss of RMB23.4 billion due to asset impairments, Fosun maintains a healthy financial position with a solid net asset base and ample cash reserves. The company focuses on core businesses and innovation to drive future growth.

Fosun International: Total Revenue in 2025 Reaches RMB173.43 Billion, with Overseas Revenue Accounting for 54.7%, Aiming to Achieve"RMB10 Billion in Profit" | FOSUF Stock News

Guo Guangchang's Letter to Shareholders: "Repair the Roof While the Sun Is Shining" -- Fosun Aims to Go Further with Greater Stability | FOSUF Stock News

Guo Guangchang's Letter to Shareholders: "Repair the Roof While the Sun Is Shining" -- Fosun Aims to Go Further with Greater Stability | FOSUF Stock News

JPFOPHA@EC2609A(27285.HK)

JPFOPHA@EC2609A Stock Performance Chart

Fosun International Holds 2025 Annual Results Presentation: Fosun has the Ability to Navigate Through Cycles | FOSUF Stock News

Fosun Pharmaceutical to Set Up Parallel Fund Structure

Fosun International (SEHK:656) Returns To Profit In H1 EPS Profit Tests Bearish Loss Narrative

Fosun Pharma Wins China Trial Nod for Teva-Partnered Cancer Drug FXB0871

Shanghai Fosun Pharma announces approval from NMPA for clinical trial of FXB0871